Wee1 kinase as a target for cancer therapy

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

(2013) A. D. Guertin et al.   MOLECULAR CANCER THERAPEUTICS

Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells

(2012) Aki Iwai et al.   CELL CYCLE

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

WEE1 inhibition sensitizes osteosarcoma to radiotherapy

(2011) Jantine PosthumaDeBoer et al.   BMC CANCER

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

(2011) Kurtis D. Davies et al.   CANCER BIOLOGY & THERAPY

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease

(2011) Raquel Domínguez-Kelly et al.   JOURNAL OF CELL BIOLOGY

WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis

(2011) S. V. Garimella et al.   MOLECULAR CANCER RESEARCH

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

(2011) Neil Johnson et al.   NATURE MEDICINE

Novel insights into maintaining genomic integrity: Wee1 regulating Mus81/Eme1

(2011) Yusé Martín et al.   Cell Division

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Hsp90 phosphorylation, Wee1 and the cell cycle

(2010) Mehdi Mollapour et al.   CELL CYCLE

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase

(2010) Halfdan Beck et al.   JOURNAL OF CELL BIOLOGY

Swe1Wee1-Dependent Tyrosine Phosphorylation of Hsp90 Regulates Distinct Facets of Chaperone Function

(2010) Mehdi Mollapour et al.   MOLECULAR CELL

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

(2009) Lyndsay M. Murrow et al.   BREAST CANCER RESEARCH AND TREATMENT

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage

(2009) Neil Johnson et al.   MOLECULAR CELL

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

(2009) Elizabeth Iorns et al.   PLoS One